Barriers for orally inhaled therapeutic antibodies.

The pulmonary route remains rare for delivering therapeutic Abs, with few approved inhaled molecules, despite promising evidence. Efforts must focus on the intertwined barriers associated to lung diseases to develop appropriate Ab-formulation-device combo ensuring optimal Ab deposition in the respiratory tract. Finally randomized controlled clinical trials should be carried out to establish inhaled Ab therapy as prominent against respiratory diseases.